Verastem | VSTM - Assets


Verastem reported $227.81M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Curis USD 29.69M 9.72M Mar/2026
Cytokinetics USD 1.92B 651.07M Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
Laboratory Of America USD 18.53B 554.8M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
TG Therapeutics USD 1.64B 110.79M Jun/2026
Verastem USD 227.81M 18.63M Mar/2026